BiotechTube
Juvise Pharmaceuticals

Juvise Pharmaceuticals

Paris, France· Est.
juvisepharmaceuticals.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Juvise Pharmaceuticals is a private, commercial-stage specialty pharma company with a unique business model centered on acquiring mature, essential medicines from larger pharmaceutical firms. It operates internationally, with a strong European manufacturing base, and focuses on therapeutic areas including Multiple Sclerosis, Gastroenterology, Oncology, Cardiology, Rheumatology, and Neuropsychiatry. The company recently expanded its portfolio and capital base by acquiring global rights (ex-US/Canada) to PONVORY® and securing investment from Bpifrance and Pemberton, signaling a phase of strategic growth.

Multiple SclerosisGastroenterologyOncologyCardiologyRheumatologyNeuropsychiatry

Technology Platform

Business model focused on acquisition, lifecycle management, and global commercialization of off-patent 'princeps' and established specialty medicines.

Opportunities

The large and steady flow of divestments from big pharma provides a deep pool of acquisition targets.
Growing global demand for reliable, cost-effective essential medicines in chronic disease areas aligns perfectly with Juvise's model.
Expanding into 'established specialty' products like PONVORY offers a path to higher-margin growth.

Risk Factors

Heavy reliance on a complex network of third-party manufacturers creates significant supply chain vulnerability.
The core mature portfolio faces perpetual generic competition and pricing pressure.
Success depends entirely on the continued ability to identify, acquire, and profitably commercialize new assets in a competitive bidding environment.

Competitive Landscape

Juvise competes with other specialty pharma companies that acquire mature products (e.g., some divisions of Viatris, Advanz Pharma, Cheplapharm) and generic manufacturers. Its differentiation lies in its focused 'essential medicines' ethos, strong European production footprint, and international commercial reach. The PONVORY acquisition pits it against other MS therapy providers in ex-US markets.

More companies in Small Molecule Drugs →More companies in France →